[Form 4] Oracle Corp Insider Trading Activity

Rhea-AI Filing Summary

Bioceres Group Limited, Bioceres LLC and THEO I SCSp filed Amendment No. 15 to their Schedule 13D on Bioceres Crop Solutions (BIOX). The group executed open-market sales and enforced pledge agreements on 08 Aug 2025 to settle financial obligations, cutting record-owned shares from 18,561,323 to 12,421,323.

Post-transaction, the reporting persons beneficially own 15,497,402 ordinary shares, equal to 24.7 % of BIOX’s 62.85 m shares outstanding. Voting power is largely shared: Bioceres Group holds 70,785 sole / 15,426,617 shared votes; Bioceres LLC 14,989,117 shared; THEO I SCSp 437,500 shared.

The filing states the disposals were undertaken solely to meet due liabilities and that the group presently has no plans or proposals regarding mergers, asset sales, board changes or other corporate actions under Item 4. No new contracts, litigation or additional agreements were disclosed.

Positive

• Reporting group retains a substantial 24.7 % stake, preserving significant influence over BIOX.
• Filing confirms no current plans for mergers, asset sales or control changes, reducing near-term strategic uncertainty.

Negative

• Ownership fell by roughly 3.1 m shares (≈5 % of outstanding) due to sales and pledge enforcement.
• Divestiture undertaken to satisfy financial obligations may signal liquidity pressure at the parent entities.

Insights

Equity Analyst

TL;DR: Position cut by 3 m shares yet remains influential; neutral-to-slightly negative signal.

The sale reduces beneficial ownership from 29.5 % (estimated) to 24.7 %, a material 3.1 m-share decline. While the group still wields meaningful control, selling to cover obligations hints at cash-flow stress at the parent level rather than confidence in BIOX. Because control is largely maintained, operational influence over the issuer is unchanged, but reduced alignment may weigh on market perception. No activist intent tempers governance risk.

Corporate Governance Specialist

TL;DR: Stake cut, pledge enforcement suggests creditor influence; modest governance concern.

Enforcement of 2022 pledge agreements means creditors forced part of the divestiture. Such events can introduce external parties into the ownership structure and imply tightened financing terms for the reporting entities. However, the remaining 24.7 % block, combined with shareholder-agreement voting rights, still grants Bioceres substantial sway over board matters. Lack of further strategic plans limits immediate governance disruption.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Magouyrk Clayton M.

(Last) (First) (Middle)

C/O DELPHI ASSET MGMT CORPORATION

200 S. VIRGINIA ST., SUITE 625

(Street)

RENO NV 89501

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ORACLE CORP [ ORCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, OCI

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/04/2025		M		62,500	A	$0	123,222	D
Common Stock	08/04/2025		F(1)		23,981	D	$244.42	99,241	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	08/03/2021		J(3)		62,500(3)		(4)	(4)	Common Stock	62,500	$0	62,500	D
Restricted Stock Unit	(2)	09/20/2022		J(3)		176,186(3)		(5)	(5)	Common Stock	176,186	$0	176,186	D
Restricted Stock Unit	(2)	09/15/2023		J(3)		184,357(3)		(6)	(6)	Common Stock	184,357	$0	184,357	D
Restricted Stock Unit	(2)	09/19/2024		J(3)		167,075(3)		(7)	(7)	Common Stock	167,075	$0	167,075	D
Restricted Stock Unit	(2)	08/04/2025		M			62,500	(4)	(4)	Common Stock	62,500	$0	0	D

Explanation of Responses:

1. Shares withheld for payment of tax liability upon vesting of restricted stock units.

2. Each restricted stock unit represents the contingent right to receive, at settlement, one share of common stock.

3. Represents unvested restricted stock units ("RSUs") awarded prior to the Reporting Person becoming a Section 16 officer on June 2, 2025, which were inadvertently omitted from the Reporting Person's Form 3 filed with the Commission on June 12, 2025.

4. Includes 62,500 unvested RSUs from a previous grant of 250,000 RSUs granted on August 3, 2021; the RSUs vest in four equal annual installments, beginning on the first anniversary of the date of the grant.

5. Includes 176,186 unvested RSUs from a previous grant of 352,372 RSUs granted on September 20, 2022; the RSUs vest in four equal annual installments, beginning on the first anniversary of the date of the grant.

6. Includes 184,357 unvested RSUs from a previous grant of 245,809 RSUs granted on September 15, 2023; the RSUs vest in four equal annual installments, beginning on the first anniversary of the date of the grant.

7. Includes 167,075 unvested RSUs from a previous grant of 167,075 RSUs granted on September 19, 2024; the RSUs vest in four equal annual installments, beginning on the first anniversary of the date of the grant.

	/s/ Aimee Weast by Aimee Weast, Attorney in Fact for Clayton M. Magouyrk (POA filed 6/12/2025)	08/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BIOX shares does Bioceres Group now own?

The reporting persons beneficially own 15,497,402 shares, or 24.7 % of BIOX’s outstanding stock.

Why did Bioceres Group sell BIOX shares in August 2025?

Shares were sold and pledged shares enforced to fund the payment of financial obligations owed by the reporting entities.

How much did Bioceres Group’s stake decrease?

Record holdings dropped from 18,561,323 to 12,421,323 shares, a reduction of about 3.1 million shares.

Does Bioceres plan any corporate actions after this filing?

The filing states the group has no current plans or proposals related to mergers, asset sales, board changes or other Item 4 matters.

What is the voting power distribution among the Bioceres entities?

Bioceres Group: 70,785 sole / 15,426,617 shared; Bioceres LLC: 14,989,117 shared; THEO I SCSp: 437,500 shared voting rights.